Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An update from Tiziana Life Sciences ( (TLSA) ) is now available.
Tiziana Life Sciences has announced promising findings regarding its nasal anti-CD3 monoclonal antibody, which shows potential in sustaining tissue homeostasis and mitigating side effects associated with the discontinuation of GLP-1 agonists. This development not only enhances the benefits of GLP-1 drugs like semaglutide but also addresses tolerability issues, potentially improving patient outcomes and offering a novel approach to treating metabolic disorders and age-related diseases.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using novel drug delivery technologies for immunotherapy. Their lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody currently in clinical development, demonstrating improved safety and efficacy over traditional intravenous delivery methods.
YTD Price Performance: 8.24%
Average Trading Volume: 326,776
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $81.45M
For a thorough assessment of TLSA stock, go to TipRanks’ Stock Analysis page.
